Skip to main content
. 2017 Dec 15;9(2):2770–2781. doi: 10.18632/oncotarget.23449

Table 1. Characteristics of studies included in the meta-analysis.

Study Country Ethnicity Design Gender
(M:F [n])		 Genotype distribution (case/control) Genotyping Method Diagnosis criteria HWE (P) NOS
(case/control) CC CT TT
Andresen V 2006 United States Caucasian
(95.1%)		 PB 31:183 /
40:112		 111/
77		 87/
62		 16/
13		 Direct
Sequencing		 Rome II 0.92 9
Camilleri M 2008 United States Caucasian HB 3:119/ 0:39 57/
19		 53/
16		 12/
4		 Direct
Sequencing		 Rome II 0.82 7
de Vries DR 2009 Netherlands Caucasian PB 66:70 /
120:253		 60/
199		 68/
138		 8/
36		 molecular beacon assay Rome II 0.10 8
Kim HG 2012 South Korea Asian HB 25:35 /
167:267		 16/
112		 31/
215		 13/
107		 TaqMan Assay Rome III 0.85 7
Lee HJ 2010 South Korea Asian HB 58:36 /
44:44		 13/
16		 49/
56		 32/
16		 PCR and
RFLP		 Rome III 0.01 7
Markoutsaki T 2011 Greece Caucasian HB 30:94/ 96:142 37/ 120 65/
97		 22/
21		 PCR and
RFLP		 Rome III 0.82 7
Park CS 2012 South Korea Asian HB 32:40/ 81:67 27/ 35 28/
79		 17/
34		 SNaPShot Rome III 0.41 7
Saito YA 2007 United States Caucasian
(> 96%)		 HB 9:41/ 10:43 25/ 24 19/
22		 6/
7		 Thermo Electron Hybaid MBS thermal cycler Rome II 0.59 7
Saito YA 2012 United States Caucasian
(> 97%)		 HB 65:320/
84:178		 122/
114		 117/
109		 28/
28		 Thermo Electron Hybaid MBS thermal cycler Rome II 0.80 7
Yoon Jin Choi 2014 South Korea Asian HB 38:61 / 85:86 26/ 40 46 /
81		 27 /
50		 TaqMan Assay Rome III 0.52 8
Yuezhi Wang 2014 China Asian HB 56:10/ 89:26 50/ 92 13/
21		 3/
2		 Real-Time PCR Rome III 0.54 7

Abbreviations: HB, hospital-based study; PB, population based; RFLP, restriction fragment length polymorphism analyses